1718 related articles for article (PubMed ID: 9618421)
21. Role of intracellular calcium in modification of mu and delta opioid receptor-mediated antinociception by diabetes in mice.
Ohsawa M; Nagase H; Kamei J
J Pharmacol Exp Ther; 1998 Aug; 286(2):780-7. PubMed ID: 9694934
[TBL] [Abstract][Full Text] [Related]
22. Effects of naloxone and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice.
Bilsky EJ; Bernstein RN; Wang Z; Sadée W; Porreca F
J Pharmacol Exp Ther; 1996 Apr; 277(1):484-90. PubMed ID: 8613958
[TBL] [Abstract][Full Text] [Related]
23. SNF9007: a novel analgesic that acts simultaneously at delta 1, delta 2 and mu opioid receptors.
Williams CL; Rosenfeld GC; Dafny N; Fang SN; Hruby VJ; Bowden G; Cullinan CA; Burks TF
J Pharmacol Exp Ther; 1994 May; 269(2):750-5. PubMed ID: 8182541
[TBL] [Abstract][Full Text] [Related]
24. Mu and delta opioid receptor desensitization in undifferentiated human neuroblastoma SHSY5Y cells.
Prather PL; Tsai AW; Law PY
J Pharmacol Exp Ther; 1994 Jul; 270(1):177-84. PubMed ID: 8035314
[TBL] [Abstract][Full Text] [Related]
25. Identification of mechanisms and sites of actions of mu and delta opioid receptor activation in the canine intestine.
Fox-Threlkeld JE; Daniel EE; Christinck F; Hruby VJ; Cipris S; Woskowska Z
J Pharmacol Exp Ther; 1994 Feb; 268(2):689-700. PubMed ID: 8113980
[TBL] [Abstract][Full Text] [Related]
26. Dissociation of opioid antinociception and central gastrointestinal propulsion in the mouse: studies with naloxonazine.
Heyman JS; Williams CL; Burks TF; Mosberg HI; Porreca F
J Pharmacol Exp Ther; 1988 Apr; 245(1):238-43. PubMed ID: 2834537
[TBL] [Abstract][Full Text] [Related]
27. 7-Benzylidenenaltrexone (BNTX): a selective delta 1 opioid receptor antagonist in the mouse spinal cord.
Sofuoglu M; Portoghese PS; Takemori AE
Life Sci; 1993; 52(8):769-75. PubMed ID: 8383271
[TBL] [Abstract][Full Text] [Related]
28. Selective antagonism by naltrindole of the antinociceptive effects of the delta opioid agonist cyclic[D-penicillamine2-D-penicillamine5]enkephalin in the rat.
Drower EJ; Stapelfeld A; Rafferty MF; de Costa BR; Rice KC; Hammond DL
J Pharmacol Exp Ther; 1991 Nov; 259(2):725-31. PubMed ID: 1658309
[TBL] [Abstract][Full Text] [Related]
29. Enhancement of morphine antinociception by a CCKB antagonist in mice is mediated via opioid delta receptors.
Vanderah TW; Bernstein RN; Yamamura HI; Hruby VJ; Porreca F
J Pharmacol Exp Ther; 1996 Jul; 278(1):212-9. PubMed ID: 8764354
[TBL] [Abstract][Full Text] [Related]
30. Involvement of adenosine in antinociception produced by spinal or supraspinal receptor-selective opioid agonists: dissociation from gastrointestinal effects in mice.
DeLander GE; Mosberg HI; Porreca F
J Pharmacol Exp Ther; 1992 Dec; 263(3):1097-104. PubMed ID: 1335055
[TBL] [Abstract][Full Text] [Related]
31. Unexpected antinociceptive potency of cyclic [D-Tca1]CTAP: potential for a novel mechanism of action.
Horan PJ; Wild KD; Kazmierski WM; Ferguson R; Hruby VJ; Weber SJ; Davis TP; Fang L; Knapp RJ; Yamamura HI
Eur J Pharmacol; 1993 Mar; 233(1):53-62. PubMed ID: 8386089
[TBL] [Abstract][Full Text] [Related]
32. Tolerance to delta- but not mu-opioid receptors in the spinal cord attenuates inhibition of the tail-flick response induced by beta-endorphin administered intracerebroventricularly in mice.
Suh HH; Tseng LF
Pharmacol Biochem Behav; 1990 Apr; 35(4):807-13. PubMed ID: 2161107
[TBL] [Abstract][Full Text] [Related]
33. DAMGO and 6beta-glycine substituted 14-O-methyloxymorphone but not morphine show peripheral, preemptive antinociception after systemic administration in a mouse visceral pain model and high intrinsic efficacy in the isolated rat vas deferens.
Al-Khrasani M; Spetea M; Friedmann T; Riba P; Király K; Schmidhammer H; Furst S
Brain Res Bull; 2007 Oct; 74(5):369-75. PubMed ID: 17845912
[TBL] [Abstract][Full Text] [Related]
34. Dual effects of DAMGO [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin and CTAP (D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2) on adenylyl cyclase activity: implications for mu-opioid receptor Gs coupling.
Szücs M; Boda K; Gintzler AR
J Pharmacol Exp Ther; 2004 Jul; 310(1):256-62. PubMed ID: 14996951
[TBL] [Abstract][Full Text] [Related]
35. Mu opioid antagonist properties of a cyclic somatostatin octapeptide in vivo: identification of mu receptor-related functions.
Shook JE; Pelton JT; Lemcke PK; Porreca F; Hruby VJ; Burks TF
J Pharmacol Exp Ther; 1987 Jul; 242(1):1-7. PubMed ID: 2886635
[TBL] [Abstract][Full Text] [Related]
36. Novel peptidic mu opioid antagonists: pharmacologic characterization in vitro and in vivo.
Kramer TH; Shook JE; Kazmierski W; Ayres EA; Wire WS; Hruby VJ; Burks TF
J Pharmacol Exp Ther; 1989 May; 249(2):544-51. PubMed ID: 2566679
[TBL] [Abstract][Full Text] [Related]
37. Multiplicative interaction between intrathecally and intracerebroventricularly administered mu opioid agonists but limited interactions between delta and kappa agonists for antinociception in mice.
Roerig SC; Fujimoto JM
J Pharmacol Exp Ther; 1989 Jun; 249(3):762-8. PubMed ID: 2567350
[TBL] [Abstract][Full Text] [Related]
38. A single residue, Lys108, of the delta-opioid receptor prevents the mu-opioid-selective ligand [D-Ala2,N-MePhe4,Gly-ol5]enkephalin from binding to the delta-opioid receptor.
Minami M; Nakagawa T; Seki T; Onogi T; Aoki Y; Katao Y; Katsumata S; Satoh M
Mol Pharmacol; 1996 Nov; 50(5):1413-22. PubMed ID: 8913373
[TBL] [Abstract][Full Text] [Related]
39. Mechanism of clocinnamox blockade of opioid receptors: evidence from in vitro and ex vivo binding and behavioral assays.
Zernig G; Burke T; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1996 Oct; 279(1):23-31. PubMed ID: 8858971
[TBL] [Abstract][Full Text] [Related]
40. Spinal interactions between opioid and noradrenergic agonists in mice: multiplicativity involves delta and alpha-2 receptors.
Roerig SC; Lei S; Kitto K; Hylden JK; Wilcox GL
J Pharmacol Exp Ther; 1992 Jul; 262(1):365-74. PubMed ID: 1378095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
